Cell News and Research

RSS

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

11 Feb 2011

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

The Massachusetts General Hospital research team that first discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including retrotransposons - also called "jumping genes" - that copy and insert themselves into other areas of the genome.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Phospholipid membranes demonstrate ability to absorb lanthanum cations

University of Granada scientists and the Spanish Higher Institute for Scientific Research (CSIC) have made significant progress in understanding lipid membranes, which are extensively employed in the development of cosmetic and drug products, and which have potential application in the field of nanotechnology.

10 Feb 2011

DNA sequencing of maternal blood plasma can accurately detect trisomy 21

In a study published online today in the American Journal of Obstetrics & Gynecology, researchers from the Sequenom Center for Molecular Medicine confirmed that DNA sequencing of maternal blood plasma could accurately detect trisomy 21.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

Patients with sensorineural hearing loss can benefit from mucosa-derived stem cell transplant

Stem Cell scientists in Australia have found that patients suffering from hearing problems which began during infancy and childhood could benefit from a transplant of stem cells from their nose. The research, published today in STEM CELLS, reveals that mucosa-derived stem cells can help preserve hearing function during the early-onset of sensorineural hearing loss.

10 Feb 2011

Photodynamic therapy could be useful in eradicating tumor-associated lymphatic vessels

Tumor cells have several routes that enable them to move from the primary tumor to distant tissues, a process called metastasis. It is metastasis of the primary tumor that kills most cancer patients. One of the least studied routes of metastasis is the lymphatic system. Many tumors produce factors that promote the formation of new lymphatic vessels (lymphangiogenesis).

10 Feb 2011

Physicist creates technology that may enhance pharma industry's early drug discovery capabilities

A Purdue physicist has created technology to detect motion inside three-dimensional tumor spheroids, which may enhance the pharmaceutical industry's early drug discovery capabilities.

10 Feb 2011

Study unveils surprising mechanism that controls brain formation

A study from The Scripps Research Institute has unveiled a surprising mechanism that controls brain formation. The findings have implications for understanding a host of diseases, including some forms of mental retardation, epilepsy, schizophrenia, and autism.

10 Feb 2011

EHSI applauds promising new stem cell treatment for Parkinson's

Emerging Healthcare Solutions, Inc. applauded a new study today revealing a promising new stem cell treatment for Parkinson's.

10 Feb 2011

Scientists generate beating heart cells from skin cells of young patients with severe genetic heart defect

Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.

10 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Study: New curcumin-hybrid compound may help protect, regenerate brain cells after stroke

Whether or not you're fond of Indian, Southeast Asian and Middle Eastern food, stroke researchers at Cedars-Sinai Medical Center think you may become a fan of one of their key spices.

10 Feb 2011

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Neuralstem, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC), currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

Cell News and Research

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

Full genetic blueprint of multiple prostate tumors laid bare

Vical 2010 net loss increases to $30.4 million

Phospholipid membranes demonstrate ability to absorb lanthanum cations

DNA sequencing of maternal blood plasma can accurately detect trisomy 21

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Breakthrough in cancer research can help reduce heart failure, increase survival rates

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Patients with sensorineural hearing loss can benefit from mucosa-derived stem cell transplant

Photodynamic therapy could be useful in eradicating tumor-associated lymphatic vessels

Physicist creates technology that may enhance pharma industry's early drug discovery capabilities

Study unveils surprising mechanism that controls brain formation

EHSI applauds promising new stem cell treatment for Parkinson's

Scientists generate beating heart cells from skin cells of young patients with severe genetic heart defect

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Study: New curcumin-hybrid compound may help protect, regenerate brain cells after stroke

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Everolimus phase III study shows improved progression-free survival in patients with pNET

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News